スポンサーサイト

上記の広告は1ヶ月以上更新のないブログに表示されています。
新しい記事を書く事で広告が消せます。


Cancer Topics Index 04/27/2016(Daily Test version/ 日刊テスト版)No.18

konpas.jpg
Cancer Topics Index 04/27/2016(Daily Test version/ 日刊テスト版) No.18

Flags 【海外:overseas】
◇FDA (U.S. Food and Drug Administration) News◇
【承認】【進行性腎細胞がん】
Cabozantinib (CABOMETYX) (April 25, 2016 FDA Approved Drugs)
On April 25, 2016, the U. S. Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. The approval was based on a randomized study in which patients with advanced renal cell carcinoma who had received prior anti-angiogenic therapy received either cabozantinib 60 mg orally once daily (N=330) or everolimus 10 mg orally once daily (N=328).

logo-clinicaltrials-gov.png
rinnsyo1.jpg
※2週間前の情報を基準として掲載。一部の記事(がんと直接関連しないもの)は割愛しています。
13 studies found for: cancer | received from 04/13/2016 to 04/13/2016

【乳がん】
1 Not yet recruiting
Comparison of Healthy Diets on Breast Cancer Markers
Condition: Breast Neoplasms
Interventions: Other: Low carbohydrate diet; Other: Low fat diet
Sponsor:Albert Einstein College of Medicine of Yeshiva University
ClinicalTrials.gov Identifier:NCT02744079

【大腸がん】
2 Recruiting
Reconstruction Techniques and Vascular Approach After Laparoscopic Left Hemicolectomy and Rectum Low Anterior Resection
Conditions: Colorectal Cancer; Rectal Tumors
Interventions: Procedure: Initially dissection of inferior mesenteric vein; Procedure: Initially dissection of inferior mesenteric artery; Procedure: Latero-terminal colorectal anastomosis; Procedure: Termino-terminal colorectal anastomosis
Sponsor:Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
ClinicalTrials.gov Identifier:NCT02746224

【神経内分泌腫瘍】
3 Not yet recruiting
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: Lutetium-177 Octreotate
Sponsor:University Health Network, Toronto
ClinicalTrials.gov Identifier:NCT02743741

【がん/妊娠】
4 Recruiting
Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes
Condition: Pregnancy,Neoplastic Complications
Intervention:
Sponsor:The Cooper Health System
ClinicalTrials.gov Identifier:NCT02749474

【乳がん】
5 Active, not recruiting
Overall Survival and Disease-free Survival in Breast Cancer Patients Under COS
Condition: Breast Cancer
Intervention: Other: Collect retrospectively the follow-up data
Sponsor:IVI Vigo
ClinicalTrials.gov Identifier:NCT02745262

【肺がん】
6 Not yet recruiting
Navigated EBUS and Functional Imaging in Lung Cancer
Condition: Bronchial Neoplasms
Intervention: Device: navigated bronchoscopy
Sponsor:St. Olavs Hospital
ClinicalTrials.gov Identifier:NCT02745002

【頭頸部がん】
7 Not yet recruiting
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Head and Neck Cancer
Interventions: Biological: Nivolumab; Biological: Ipilimumab; Drug: Cetuximab/Erbitux; Drug: Cisplatin/Platinol; Drug: Carboplatin/Paraplatin; Drug: Fluorouracil/Adrucil
Sponsor:Bristol-Myers Squibb
ClinicalTrials.gov Identifier:NCT02741570

【乳房切除】
8 Recruiting
Comparison of Perioperative Opioid Consumption Following Pectoral Nerve Block for Breast Cancer Surgery
Conditions: Nerve Block; Mastectomy
Interventions: Drug: Lidocaine 1% with epinephrine 1/400000; Other: sham block
Sponsor:Maisonneuve-Rosemont Hospital
ClinicalTrials.gov Identifier:NCT02741232

【乳房切除後疼痛症候群(PMPS)】
9 Not yet recruiting
Efficiency of Acupuncture-assisted Anesthesia With Single Acupoint or Dual Acupoints in Patients Undergoing Radical Operation of Breast Cancer
Condition: Pain
Interventions: Device: dual acupoints TEAS; Device: single acupoint TEAS; Device: false TEAS
Sponsor:Zhihong LU
ClinicalTrials.gov Identifier:NCT02741726

【白血病】
10 Recruiting
Evaluation of the Effectiveness of an Aldehyde Inhibitor Dehydrogenases (DIMATE) on the Cell Population Leukemic or Normal Stem
Condition: Leukemia
Interventions: Biological: blood sample; Biological: Stem cell donation
Sponsor:Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier:NCT02748850

【小児髄芽腫】
11 Recruiting
Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma
Condition: Medulloblastoma
Intervention:
Sponsor:St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier:NCT02747576

【大腸がん】
12 Recruiting
Efficacy of Acupuncture in Prevention of Chemotherapy Induced Peripheral Neuropathy - a Pilot Study
Condition: Colorectal Cancer
Intervention: Other: Verum acupuncture
Sponsor:Tzu-Liang Chen
ClinicalTrials.gov Identifier:NCT02744274

【神経膠芽腫】
15 Recruiting
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
Conditions: Glioblastoma; Diffuse Intrinsic Pontine Glioma
Intervention: Drug: DSP-7888
Sponsor:Sumitomo Dainippon Pharma Co., Ltd.
ClinicalTrials.gov Identifier:NCT02750891

animated-european-union-flag.gif
◇EU, EMA, CHMP, Cancer Research UK, NICE◇
2653833040_644faff824_b.jpg
【DNAシーケンシング技術の進歩】
Everything you really need to know about DNA sequencing (April 25, 2016 Misha Gajewski Science blog)
It’s becoming increasingly clear cancer is a disease rooted in our genes. But figuring out how our genes control cancer is a mystery that is still very much unresolved.However, recent advances in DNA sequencing technology are helping us piece the clues together – and the more we find out, the closer we get to better treatments.So how exactly does that technology work, and how is it helping? To answer that question we have to go back to where it all began.

<Medical Journal & Other News>
headline.jpg
【急性骨髄性白血病/マイクロRNAの特定シグナル伝達経路】JOURNAL:Nature Communications
MicroRNA pathway could lead to new avenues for leukemia treatment (04/26/2016 EurekAlert!/UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER)
CINCINNATI--Cancer researchers at the University of Cincinnati (UC) have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.These findings are being published in the April 26 issue of the online journal Nature Communications.

【新しい肝細胞がん予後モデル】JOURNAL:PLOS Medicine
New hepatocellular carcinoma prognostic model improves prediction of patient survival (04/26/2016 EurekAlert!/PLOS)
The ITA.LI.CA prognostic system, a model integrating tumor staging, liver function, functional status, and alpha-fetoprotein level, builds on previous models of hepatocellular carcinoma (HCC) prognosis and shows superior survival prediction in Italian and Taiwanese cohorts, according to a study published this week in PLOS Medicine by Alessandro Vitale of Azienda Ospedaliera Universitaria di Padova, Italy, and colleagues.

【ワクチン開発のブレイクスルー】JOURNAL:Journal of Nanobiotechnology
Danish researchers behind vaccine breakthrough (04/26/2016 EurekAlert!/UNIVERSITY OF COPENHAGEN THE FACULTY OF HEALTH AND MEDICAL SCIENCES)
The next generation of vaccines may soon see the light of day, because Danish researchers have discovered a completely new and simple method which sets new standards for the development of vaccines."The major research breakthrough is that we have created a general and user-friendly platform for the development of a special type of effective and safe vaccines. The highly effective method opens a new door for controlling diseases such as cancer, asthma, allergies and cardiovascular diseases by means of vaccines. We are therefore already now able to initiate strategies to combat some of the biggest killers in the western world," says Postdoc Adam Sander, Department of Immunology and Microbiology, University of Copenhagen.

telomeres.jpg
【老化】
FIRST GENE THERAPY SUCCESSFUL AGAINST HUMAN AGING (04/21/2016 bioviva-science.com)
人間の老化に対する初の遺伝子治療が成功か (04/25/2016 Gigazine)

<Topics>

【生きること】
7 Wonders of the World in 13 Days MEGAN SULLIVAN(megthelegend.com)
人生を変えるのは自分なのだ——癌と宣告された女性。彼女はその2週間後、世界をめぐる旅へと出発した (04/25/2016 Pouch)

【生物学的療法】全文の翻訳です ※林 正樹(血液・腫瘍内科/社会医療法人敬愛会中頭病院)監修/生田亜以子 訳
Biological Therapies for Cancer (National Cancer Institute website)
がんに対する生物学的療法(生物療法)(04/21/2016 海外癌情報リファレンス)

Graphics 【日本国内:Japan】
<Press Release:日本国内>
【がんゲノムレポート】
がん細胞の遺伝子を解析し、解析情報及び最新治験情報等を医師に提供する「P5がんゲノムレポート」サービスを開始:個々のがん患者へのより適切な治療提供をサポート (04/24/2016 P5,Inc)
同一の臓器のがん細胞においても、遺伝子の変異は単一ではないため、変異した遺伝子の種類ごとに分子標的薬の種類も異なります。そのため、がん患者の治療の最適化に向けては、個々の患者の遺伝子変異情報を把握し、最適な分子標的薬を投与する必要があります。P5は、最新技術を駆使して得られた遺伝子変異情報に加え、効果を示す可能性のある薬剤やその遺伝子変異を持つがんに適した国内外の最新治験情報などを合わせてレポートにまとめ、がん患者の主治医に提供します。P5が医師に提出するレポートは、医師ががん患者に対するより適切な治療を判断していくうえで、役立てて頂く可能性のある情報となります。
P5,Inc (website)

<厚生労働省(MHLW)/文部科学省(MEXT)・その他省庁>
【KAKEN】
KAKEN-科学研究費助成事業データベースのリニューアルについて (04/26/2016 文部科学省:MEXT)
KAKEN-科学研究費助成事業データベース (website)

【がん教育】
学校におけるがん教育の在り方について (04/25/2016 文部科学省:MEXT)
保護者も学べる学校向け「がん」教育教材公開…文部科学省 (04/25/2016 リセマム)

【疾病・障害認定】
第113回疾病・障害認定審査会感染症・予防接種審査分科会 (04/22/2016 厚生労働省:MHLW)
子宮頸がんワクチンなど9件の疾病障害認定- 厚労省が公表、睡眠障害も (04/25/2016 CBnews)

<News>
【一番大事なもの】
「抗がん剤の是非」を巡る論争は、不毛である がん患者にとって一番大事なものは何か 高野 利実 :虎の門病院臨床腫瘍科部長 (04/27/2016 東洋経済Online)
がんとともに、自分らしく生きる (Amazon)

【現状と課題】
知っておきたい医療のこと:日本のがん医療の現状と課題 北青山Dクリニック 院長 阿保 義久(04/27/2016 ITmedia)

【子宮体がん】
村田喜代子さん新刊「焼野まで」 がん闘病から生命の根源へ迫る (04/27/2016 産経ニュース)
焼野まで (小説)

【薬食審・第二部会】
薬食審・第二部会 新薬3製品を審議、承認了承 全てがん領域製品 (04/26/2016 ミクスOnline)

【子宮頸がん】
30代ママが子宮頸がんになりやすい理由 - 女性ホルモンとがんの関わりとは (04/26/2016 マイナビニュース)

【肺腺がん】
【がん電話相談から】肺腺がん、肺切除後の呼吸器障害は? (04/26/2016 産経ニュース)

<新刊メタデータ:New Books>
book_sepia.jpg
【タイトル】がんとともに、自分らしく生きる:希望をもって、がんと向き合う「HBM」のすすめ
著者:高野 利実/単行本(ソフトカバー): 240ページ/出版社: きずな出版 (2016/3/24)/ISBN-10: 4907072589/ISBN-13: 978-4907072582/¥1,728 Kindle版¥1,279

【タイトル】焼野まで (小説)
著者:村田 喜代子/単行本: 256ページ/出版社: 朝日新聞出版 (2016/2/5)/ISBN-10: 4022513586/ISBN-13: 978-4022513588/¥1,728
関連記事


コメント
コメントの投稿


管理者にだけ表示を許可する

トラックバック
http://paxxmedia.blog38.fc2.com/tb.php/9092-7a1f3304
この記事にトラックバックする(FC2ブログユーザー)


上記広告は1ヶ月以上更新のないブログに表示されています。新しい記事を書くことで広告を消せます。